《大行報告》摩通上調創科(00669.HK)目標價至180元 評級「增持」
摩根大通發表研究報告,將創科實業(00669.HK)2021至2023年盈利預測上調11%,預期在美國刺激經濟措施帶動下,工業、商業及零售渠道需求增加,預期公司透過推出更多無線工具可提升市場份額。
該行指,創科預期除MX FUEL系列於2023年起才貢獻一定收入外,其他產品銷售前景均向好,認為全年收入增長較公司訂立的目標仍有提升空間,儘管原材料及運輸成本上升,但公司有信心毛利率可維持上升趨勢。
摩通指,創科是擁有眾多創新產品的行業龍頭,給予「增持」評級,目標價由151元上調至180元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.